Tumor Glycomics Laboratory for Discovery of Pancreatic Cancer Markers

描述（由申请人提供）：胰腺癌是美国癌症死亡的第四大原因。2006年，32,180人将被诊断为胰腺癌，31,180人将死于胰腺癌，每小时4个美国人。胰腺癌是所有癌症中1年和5年预后最差的（分别为4%和1%）。这种疾病的高死亡率主要是由于缺乏早期诊断的手段。因此，RFA应用的长期目标是将新开发的糖基化技术应用于胰腺癌血清标志物的开发。胰腺癌在某种程度上是独特的，因为可以直接收集含有癌症分泌物的胰腺导管液，这些分泌物很可能含有潜在的糖蛋白和糖脂生物标志物。对来自胰腺癌和对照胰腺的这种液体进行糖组分析，再加上来自胰腺组织的信息，包括糖转录组分析，将使我们能够专注于作为胰腺癌患者血清中潜在标记物的特定糖偶联物。我们的胰腺癌肿瘤糖组学实验室代表了乔治亚大学复杂碳水化合物研究中心的研究人员之间的合作，包括NCRR生物医学糖组学中心的成员，以及凤凰城TGen研究所的临床研究人员，他们是胰腺癌专家。目的:1。胰管液和对照（包括胰腺炎患者）的糖糖分析（聚糖、糖蛋白和鞘糖脂分析）。2. 胰腺癌、非疾病对照和胰腺炎患者的糖组分析（聚糖、糖蛋白、鞘糖脂和糖转录组分析）。3. 胰腺癌潜在血清标志物的鉴定及检测进展。4. 初步评价标志物的特异性和敏感性。TGen及其国际胰腺癌研究小组（该小组涉及全球26个机构）以及NCI胰腺癌EDRN，将负责收集用于分析的标本。

DESCRIPTION (provided by applicant): Pancreatic cancer is the 4th leading cause of cancer deaths in the U.S. In 2006, 32,180 will be diagnosed with pancreatic cancer and 31,180 will die from it-4 Americans every hour. Pancreatic cancer has the worst 1 and 5 year prognosis of any cancer (4% and 1%, respectively). The high mortality rate for this disease is due mainly to the lack of a means for its early diagnosis. The long-term goal of this RFA application, therefore, is to apply newly developed glycomic technologies to the development of serum markers for pancreatic carcinoma. Pancreatic cancer is somewhat unique in that it is possible to directly collect pancreatic ductal fluid that contains secretions from the cancer which is very likely to contain potential glycoprotein and glycolipid biomarkers. Glycomic analysis of this fluid from pancreatic cancers and control pancreases, coupled with information from pancreatic tissues, including glycotranscriptome analysis, will enable us to focus on specific glyconjugates as potential markers in serum from pancratic cancer patients. Our Tumor Glycomics Laboratory for Pancreatic Cancer represents a collaboration between investigators at the Complex Carbohydrate Research Center at the University of Georgia, including members of the NCRR Center for Biomedical Glycomics, and clinical researchers at the TGen Institute, Phoenix, who are pancreatic cancer specialists. Aims: 1. Glycomic analysis (glycan, glycoprotein, and glycosphingolipid analyses) of pancreatic ductal fluid and controls, including patients with pancreatitis. 2. Glycomic analysis (glycan, glycoprotein, glycosphingolipid, and glycotranscriptome analyses) of pancreatic carcinoma, non-diseased controls, and pancreases exhibiting pancreatitis. 3. Identification of potential serum markers of pancreatic carcinoma and assay development. 4. Initial evaluation specificity and sensitivity of markers. Collection of specimens for analysis will involve TGen and its international Pancreatic Cancer Research Team that involves 26 institutions world-wide, as well as the NCI EDRN for Pancreatic Cancer.